Nebie Koumpingnin, Sawadogo Salam, Sawadogo Salifo, Koulidiati Jérôme, Lengani Habi Y A, Sawadogo Abdoul G, Babinet Jérôme, Khalloufi Mohammed, Diop Saliou, Kafando Eléonore
National Blood Center of Ouagadougou, Ouagadougou, Burkina Faso.
Laboratory of Haematology, Department of Fundamental Sciences, Health Sciences Research and Training Unit, University Joseph KI-ZERBO, Ouagadougou, Burkina Faso.
Afr J Lab Med. 2022 Sep 26;11(1):1625. doi: 10.4102/ajlm.v11i1.1625. eCollection 2022.
In Burkina Faso, red blood cell (RBC) transfusion remains the crucial anaemia treatment following chronic renal failure (CRF) as erythropoietin and its analogues are unavailable. However, blood group matching beyond the ABO and Rhesus is not common in Burkina Faso. Thus, alloimmunisation is a potential issue for transfused patients.
Our study aimed to identify anti-erythrocyte antibodies in multi-transfused CRF patients at the Yalgado Ouedraogo Teaching Hospital, Ouagadougou, Burkina Faso.
This cross-sectional study, conducted from October 2018 to November 2019, included CRF patients who had received at least two RBC units. We screened patients for the presence of RBC antibodies using three commercial Cells panels and identified antibody specificities for positive screenings using 11 Cells panels for an indirect antiglobulin test (IAT) in a low ionic strength microcolumn gel-card system.
Two hundred and thirty-five patients (45.1% female; average age: 41.5 years) were included. The median number of blood units received per patient was 10 (interquartile range: 5-20). The overall alloimmunisation rate was 5.9% (14/235). Antibodies identified included: anti-D (1 case), anti-C (1 case), anti-D+C (4 cases), anti-C (1 case), anti-E (1 case), anti-S (1 case) and anti-Le (1 case). In four positive patients, the specificity of the antibodies was indeterminate. No risk factors were associated with alloimmunisation.
In Burkina Faso, screening for RBC alloantibodies should be mandated for patients at risk. The high rate of indeterminate antibodies suggests the need to develop a local RBC antibody panel adapted to the local population.
在布基纳法索，由于促红细胞生成素及其类似物无法获得，红细胞（RBC）输血仍然是慢性肾衰竭（CRF）后至关重要的贫血治疗方法。然而，在布基纳法索，除ABO和恒河猴血型匹配外的血型匹配并不常见。因此，同种免疫是输血患者的一个潜在问题。
我们的研究旨在确定布基纳法索瓦加杜古Yalgado Ouedraogo教学医院多次输血的CRF患者中的抗红细胞抗体。
这项横断面研究于2018年10月至2019年11月进行，纳入了至少接受过两个红细胞单位输血的CRF患者。我们使用三种商用细胞板对患者进行红细胞抗体筛查，并在低离子强度微柱凝胶卡系统中使用11种细胞板进行间接抗球蛋白试验（IAT）来确定阳性筛查的抗体特异性。
共纳入235例患者（45.1%为女性；平均年龄：41.5岁）。每位患者接受的血液单位中位数为10（四分位间距：5 - 20）。总体同种免疫率为5.9%（14/235）。鉴定出的抗体包括：抗-D（1例）、抗-C（1例）、抗-D + C（4例）、抗-c（1例）、抗-E（1例）、抗-S（1例）和抗-Lea（1例）。在4例阳性患者中，抗体特异性不确定。没有危险因素与同种免疫相关。
在布基纳法索，应对有风险的患者进行红细胞同种抗体筛查。不确定抗体的高发生率表明需要开发适合当地人群的本地红细胞抗体板。
